Loading clinical trials...
Loading clinical trials...
Phase I Trial of a Chimeric (Trastuzumab-like and Pertuzumab-like) HER2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant for Locally Advanced HER2 Positive Breast Cancer
Conditions
Interventions
HER2 Vaccine
Locations
1
United States
Indiana University Melvin & Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Start Date
June 1, 2026
Primary Completion Date
December 1, 2029
Completion Date
March 1, 2030
Last Updated
April 22, 2026
NCT04541381
NCT03137095
NCT07547774
NCT07040891
NCT06393374
NCT06257264
Lead Sponsor
Pravin T.P Kaumaya
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions